Aveanna Healthcare Holdings Inc. (ticker: AVAH) traded at $14.04, virtually at its 52‑week high, after hitting an all‑time high of $14.01. Raymond James lifted its price target from $13.00 to $15.00 while maintaining a Strong Buy rating, and RBC Capital increased its target from $10.00 to $16.00 with an Outperform rating. The stock’s one‑year change stands at 68.46% and its six‑month return at 87%.
In the second quarter of 2026, Aveanna reported revenue of $670.5 million, surpassing the consensus forecast of $638.62 million and representing a 13.7% year‑over-year increase. The company’s market capitalization is approximately $3.05 billion. Aveanna cited strong demand across its three business segments and raised its full‑year outlook.
Analyst sentiment was bolstered by nine upward earnings revisions noted by InvestingPro Tips. The firm also disclosed a secondary offering of 15 million shares by certain stockholders, with an additional option for 2.25 million shares.
Price target adjustments were influenced by an impending California private duty nursing rate increase set for January 2027 and the company’s alignment with the Ensuring Access to Medicaid Services rule.
